CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
BTG Plc Company Snapshot
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. The Interventional Medicine segment includes oncology, vascular and pulmonology. The segment's products include Beads, TheraSphere, EkoSonic, Varithena and PneumRx Coils for use in the treatment of liver tumors, blood clots, varicose veins and advanced emphysema. The Specialty Pharmaceuticals segment includes CroFab, DigiFab, Voraxaze and Vistogard products for use in the treatment of crotalid envenomation, digoxin toxicity, high-dose methotrexate toxicity and 5-fluorouracil toxicity. The Licensing segment includes Zytiga, Two-Part Hip Cup and Lemtrada products for use in the treatment of advanced prostate cancer, hip replacement and multiple sclerosis.

Sales Analysis. BTG Plc reported sales of £570.50 million (US$742.84 million) for the fiscal year ending March of 2017. This represents an increase of 27.5% versus 2016, when the company's sales were £447.50 million. Sales at BTG Plc have increased during each of the previous five years (and since 2012, sales have increased a total of 190%).
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
BTG Plc
  Stock Performance Chart for BTG Plc
 
  Stock Data: Recent Stock Performance:
  Current Price (5/19/2017): 637.00p
(Figures in Pounds Sterling)
1 Week -12.7%   13 Weeks -0.9%  
4 Weeks 13.8%   52 Weeks -1.6%  
 
BTG Plc Key Data:
  Ticker: BTG Country: United Kingdom
  Exchanges: LON Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2017 Sales 570,500,000
(Year Ending Jan 2018).
Employees: 1,182
  Currency: Pounds Sterling Market Cap: 2,453,262,334
  Fiscal Yr Ends: March Shares Outstanding: 385,127,525
  Share Type: Ordinary Closely Held Shares: 3,667,420
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.